Tagged With Gene Therapy

We got an inside look at how the biotech Spark used mazes to develop a first-of-its-kind treatment for eye disease on the way to selling itself for $4.8 billion


Elizabeth Warren and Bernie Sanders just slammed the Swiss drug giant Novartis over a new controversy swirling around the world's most expensive drug


Aetna and Anthem will now pay for more kids with a devastating rare disease to get a $2.1 million drug, reversing earlier denials



Dispensed: A big week for digital health IPOs, what happens when a $2.1 million drug can't get to the kids who need it, and what a top health-tech VC is looking to invest in


'Like we were being forced to gamble with our son's life': Health insurers won't pay for a $2.1 million drug for kids, and parents say they're running out of time


The US just approved a $2.1 million treatment for a devastating disease. It's the most expensive drug in the world.



Dispensed: Introducing Business Insider's 10 people transforming healthcare


There's now a cure for the deadly genetic disorder known as 'bubble-boy' disease


Big pharma's big bets, a hedge-fund rivalry, and Silicon Valley's obsession with failing forward


The top scientist at AveXis told us the 'unique' strength that powered its $9 billion sale to Novartis, and it could shape the future of gene therapy


Dispensed: Layoffs at Clover Health, a troubling marijuana-linked syndrome, and what's ahead for the exploding gene therapy field


Dispensed: Change at the FDA, insurance startup financials for 2018, and the first new depression drug in 35 years



Drugs that cost as much as a house are on the way to treat rare and devastating diseases. The US is scrambling to figure out how to pay for them.


Swiss drug giant Roche reportedly readies to buy the biotech behind the first FDA-approved gene therapy and the priciest medicine in the US


A revolutionary drug that could treat a rare and devastating disease is prohibitively expensive. But one state has a plan to pay for its potential $5 million price tag.


Dispensed: A $74 billion mega-merger starts 2019 off with a bang and how a health system plans to disrupt itself before it's disrupted



A new kind of one-time treatment is revolutionising the way we treat diseases like cancer and blindness, but not a lot of patients are using it


Akouos, a biotech startup that's trying to tackle a $750 billion global problem, just announced it's raised a new funding round


Novartis just handed out a $8.7 billion endorsement for new therapies that are changing how we treat genetic diseases


The FDA just approved the first gene therapy to treat blindness